Education
About Us
Working with TipRanks
Follow Us
908 Devices Inc. (MASS)
NASDAQ:MASS
MASS Stock Chart & Stats
$6.20
-$0.07(-3.29%)
At close: 4:00 PM EST
$6.20
-$0.07(-3.29%)
Day’s Range― - ―
52-Week Range$1.92 - $9.34
Previous CloseN/A
Volume74.64K
Average Volume (3M)351.49K
Market Cap
$237.06M
Enterprise Value$178.62M
Total Cash (Recent Filing)$112.05M
Total Debt (Recent Filing)$4.35M
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Mar 10, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding36,192,978
10 Day Avg. Volume377,002
30 Day Avg. Volume351,490
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)0.65
Price to Sales (P/S)1.26
P/FCF Ratio-2.43
Enterprise Value/Market Cap0.75
Enterprise Value/Revenue3.10
Enterprise Value/Gross Profit6.28
Enterprise Value/Ebitda-4.77
Forecast
1Y Price Target
$8.00Price Target Upside29.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Profitability TrajectoryAnalyst points out that the company delivered its best adjusted EBITDA performance in public company history and reaffirmed a path to positive adjusted EBITDA and cash-flow breakeven by FY26, which improves the earnings outlook.
Revenue Growth DriversAnalyst highlights that the revenue beat was driven by strength in state and local channels, an international ramp-up of VipIR, and higher sales to federal and defense customers, supporting upside to top-line expectations for 2026.
Valuation UpsideAnalyst observes that shares trade at a substantial discount to industry peers on 2026 revenue estimates, implying potential upside if valuation multiples re-rate after continued execution.
Bears Say
Government Contract RiskAnalyst warns that ongoing U.S. government shutdown-related delays put about $4 million of expected revenue at risk, creating downside pressure on near-term results.
Guidance And Sentiment DisappointmentAnalyst notes that the reiteration of guidance instead of an anticipated raise triggered a sharp share pullback, reflecting investor disappointment with forward guidance visibility.
Pipeline Concentration RiskAnalyst cautions that fourth-quarter targets depend on securing a few larger enterprise deals, making results vulnerable if those opportunities do not close as forecast.
908 Devices News
MASS FAQ
What was 908 Devices Inc.’s price range in the past 12 months?
908 Devices Inc. lowest stock price was $1.92 and its highest was $9.34 in the past 12 months.
What is 908 Devices Inc.’s market cap?
908 Devices Inc.’s market cap is $237.06M.
When is 908 Devices Inc.’s upcoming earnings report date?
908 Devices Inc.’s upcoming earnings report date is Mar 10, 2026 which is in 28 days.
How were 908 Devices Inc.’s earnings last quarter?
908 Devices Inc. released its earnings results on Nov 10, 2025. The company reported -$0.041 earnings per share for the quarter, beating the consensus estimate of -$0.145 by $0.104.
Is 908 Devices Inc. overvalued?
According to Wall Street analysts 908 Devices Inc.’s price is currently Undervalued.
Does 908 Devices Inc. pay dividends?
908 Devices Inc. does not currently pay dividends.
What is 908 Devices Inc.’s EPS estimate?
908 Devices Inc.’s EPS estimate is -0.07.
How many shares outstanding does 908 Devices Inc. have?
908 Devices Inc. has 36,192,978 shares outstanding.
What happened to 908 Devices Inc.’s price movement after its last earnings report?
908 Devices Inc. reported an EPS of -$0.041 in its last earnings report, beating expectations of -$0.145. Following the earnings report the stock price went down -13.279%.
Which hedge fund is a major shareholder of 908 Devices Inc.?
Currently, no hedge funds are holding shares in MASS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
908 Devices Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.00 (29.03% Upside)
$8.00 (29.03% Upside)
Blogger Sentiment
Bullish
MASS Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 340.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 4.9%
Last 30 Days ▲ 4.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
156.86%
12-Months-Change
Fundamentals
Return on Equity
-42.72%
Trailing 12-Months
Asset Growth
7.06%
Trailing 12-Months
Company Description
908 Devices Inc.
908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry (Mass Spec) devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of gas, liquid, and solid materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. It operates in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts.
MASS Company Deck
MASS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a mixed outlook with strong sequential growth, improvements in profitability metrics, and a robust cash position. However, these positives are counterbalanced by the year-over-year revenue decline, potential impacts from the U.S. Government shutdown, and challenges in maintaining gross margins.View all MASS earnings summariesMASS Stock 12 Month Forecast
Average Price Target
$8.00
▲(29.03% Upside)
Technical Analysis
Senseonics Holdings
―
Quanterix
―
Nano-X Imaging
―
TriSalus Life Sciences
―
Cytek Biosciences
―
Ownership Overview
Currently, No data available
---